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Abstract
PURPOSE: To evaluate the tumor-inducing ability of a few leukemic cells
xenotransplanted inside an artificial ovary. METHODS: Ten and 100 BV-173
leukemic cells were embedded in a fibrin matrix along with 50,000 human
ovarian stromal cells, and grafted to the peritoneal bursa of 5 and 5 SCID mice
respectively. Four mice grafted with 3x10(6) leukemic cells in fibrin served as
positive controls. At 20 weeks post-transplantation, the grafts, liver, spleen, blood
and bone marrow were analyzed for the presence of leukemia by anti-CD79α
IHC, flow cytometry (FC) and PCR. RESULTS: All mice grafted with 3x10(6) cells
developed peritoneal masses 4 weeks after xenotransplantation, and systemic
disease was confirmed by IHC, PCR and FC. Among mice grafted with 10 or 100
leukemic cells, none showed any sign of leukemia after 20 weeks, and IHC, FC
and PCR on the different recovered tissues all proved negative. CONCLUSION:
This study investigates the tumor-inducing potential of a few leukemic cells ...
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Abstract
Purpose To evaluate the tumor-inducing ability of a few leu-
kemic cells xenotransplanted inside an artificial ovary.
Methods Ten and 100 BV-173 leukemic cells were embedded
in a fibrin matrix along with 50,000 human ovarian stromal
cells, and grafted to the peritoneal bursa of 5 and 5 SCIDmice
respectively. Four mice grafted with 3x106 leukemic cells in
fibrin served as positive controls. At 20 weeks post-transplan-
tation, the grafts, liver, spleen, blood and bone marrow were
analyzed for the presence of leukemia by anti-CD79α IHC,
flow cytometry (FC) and PCR.
Results All mice grafted with 3x106 cells developed peritone-
al masses 4 weeks after xenotransplantation, and systemic
disease was confirmed by IHC, PCR and FC. Among mice
grafted with 10 or 100 leukemic cells, none showed any sign
of leukemia after 20 weeks, and IHC, FC and PCR on the
different recovered tissues all proved negative.
Conclusion This study investigates the tumor-inducing poten-
tial of a few leukemic cells grafted inside an artificial ovary.
Transplantation of 100 leukemic cells appears to be insuffi-
cient to induce leukemia after 20 weeks. These results in an
immunodeficient xenografting model are quite reassuring.
However, for clinical application, follicle suspensions must
be purged of leukemic cells before grafting, as even the
slightest risk should be avoided.
Keywords Artificial ovary . Leukemia . Ovarian tissue
cryopreservation . Ovarian follicles . Malignant cell purging .
Minimal disseminated disease . Follicle isolation
Introduction
Early detection and increasingly effective anti-cancer thera-
pies have led to a rise in post-cancer survival rates in recent
decades. Today, the 5-year survival rate after childhood and
adolescent cancer stands at around 82 % [1, 2]. In the United
States alone, an estimated 379,112 survivors of childhood and
adolescent cancer (diagnosed between birth and 19 years)
were alive as of January 1, 2010 [2]. For these young patients,
recovery of ovarian function and reproductive potential after
treatment have become important quality-of-life issues. Vari-
ous chemotherapeutic agents, particularly alkylating agents,
have been identified as gonadotoxic, and pelvic or total body
irradiation (TBI) can cause irreversible gonadal damage [3–5],
potentially leading to infertility problems and premature ovar-
ian failure (POF) [3–9]. This risk depends on the patient’s age
and follicle reserve, as well as the type and dose of drug
received, and is not always easy to predict. The risk of relapse
Capsule The tumor-inducing ability of a few BV-173 leukemic cells was
evaluated in an artificial ovary by xenotransplantation. One hundred BV-
173 cells proved insufficient to induce disease in mice after 20 weeks.
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and potential need for more aggressive treatments should also
be taken into account [10], so that adequate fertility preserva-
tion options can be offered to these patients before starting
cancer treatment.
Leukemia is the most common malignant disease in
childhood (0–14 years), responsible for almost one-third
of all tumors diagnosed at this age [11]. Hematological
malignancies represent the most frequent indication for
ovarian tissue cryopreservation (OTC) in our department,
with leukemia accounting for 11 % of procedures [12].
Acute lymphoblastic leukemia (ALL) patients are at low
risk (<20 %) of POF, while those with acute myeloblastic
leukemia (AML) are at medium risk (20–80 %), according
to the classification by Wallace et al. [4] based on current
treatments. Some of these patients will, however, switch to
the high-risk category (>80 % POF) in case of relapse or
incomplete response to treatment. Indeed, changing categories
occurred in around 21 % of patients (3/14) with acute leuke-
mia in one report [10].
Leukemia patients are often prepubertal and generally
require immediate chemotherapy that cannot be delayed,
so embryo and oocyte cryopreservation or fertility preser-
vation options involving ovarian stimulation cannot be
proposed to these young women [13–16]. OTC before
treatment is the only available option in these cases.
However, the safety of retransplantation of frozen-thawed
ovarian tissue in case of hematological malignancy remains of
great concern because of the risk of returning malignant cells
back to the patient. Several studies have identified malignant
cells in cryopreserved ovarian tissue of leukemia patients by
sensitive PCR [17–19] and flow cytometry [20] analysis. In
one study, the tumor-inducing potential of leukemic cells pres-
ent in ovarian tissue was demonstrated in a xenografting mod-
el [18]. In another study, however, ovarian tissue from patients
in complete remission did not appear to contain any viable
malignant cells; although PCR results were positive, none
of the grafted mice developed the disease [21]. Given the
presence of leukemic cells and the uncertainty of disease
transmission, reimplantation of ovarian tissue in young
women with the acute form of leukemia is not currently
recommended [13, 22, 23].
For this reason, our team has been working on the grafting
of individual ovarian follicles, enzymatically isolated from
frozen-thawed ovarian tissue and embedded in 3-D matrices
[24–28]. Addition of ovarian stromal and endothelial cells to
the matrix was found to be crucial for the formation of a well
vascularized ovary-like structure [29]. This artificial ovary
provides a more natural environment for follicle survival and
development, and the first studies are encouraging [25, 28].
A technique for isolation of human preantral follicles fol-
lowing good manufacturing practice (GMP) conditions was
recently optimized by our team with a view to clinical appli-
cation [30]. In this setting, however, isolated follicles would
be retrieved from cryopreserved ovarian tissue that could pos-
sibly be contaminated with cancer cells. A study was therefore
conducted to evaluate the safety of our follicle pick-up tech-
nique when leukemic cells were added to digested ovarian
tissue suspensions (Soares et al., submitted). We detected leu-
kemic cell contamination of our follicle suspensions after
pick-up, raising questions about the capacity of a few leuke-
mic cells to reintroduce the disease. The present study was
initiated to investigate the leukemia-inducing potential of a
few leukemic cells grafted in an artificial ovary environment
using an immunodeficient mouse xenografting model. Leuke-
mic cells were embedded in a fibrin matrix along with ovarian
cells (essentially stromal and endothelial cells) in order to
study leukemic cell survival and proliferation in conditions
resembling the artificial ovary environment as closely as
possible.
Materials and methods
Ten and 100 leukemic cells were embedded in a fibrin matrix
along with ovarian cells and grafted to the peritoneal bursa of
5 and 5 immunodeficient mice respectively for 20weeks. Four
mice grafted with 3 million BV-173 cells inside a fibrin matrix
served as positive controls.
Ovarian tissue digestion and stromal cell isolation
Human ovarian biopsies were taken in order to retrieve ovar-
ian cells to embed in the matrix together with leukemic cells.
Only ovarian cells but no follicles were added, as the latter
were not required for this study design. Besides, follicles are
precious material and their isolation is quite time-consuming.
Use of human tissue for this study was approved by the
Institutional Review Board of the Université Catholique de
Louvain (IRB, 2012, 125). Informed consent was obtained
before taking ovarian biopsies from 2 premenopausal
women with regular cycles (48 and 49 years of age) un-
dergoing laparoscopic surgery for benign gynecological
disease. The tissue was initially processed as previously
described [30, 31]. Cortical strips, sectioned into pieces
of 0.5×0.5×1 mm using a MclIwain Tissue Chopper
(Mickle Laboratory, UK), were incubated with 0.28Wünsch
units/mL Liberase DH (Roche Diagnostics) for 75 min at
37 °C with gentle agitation. Tissue digestion was halted by
addition of 10 ml of cold phosphate-buffered saline (PBS)
supplemented with 10 % fetal bovine serum (FBS). The
ovarian cell suspension was then successively filtered
through sterilized 80 and 11 μm nylon net filters (Millipore,
Brussels, Belgium). The obtained suspension was centri-
fuged (1200 rpm, 5 min) and the pellet resuspended in
500 μL of PBS supplemented with 10 % FBS. Ovarian
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cells were counted in a Bürker chamber and their concen-
tration adjusted to 10,000 cells/μL by centrifugation.
Leukemic cells
The BV-173 cell line was derived from a patient with Phila-
delphia chromosome-positive ALL (BCR-ABL b2-a2 fusion
gene). This cell line was obtained from DSMZ (DSMZ no.
ACC 20, Germany) and cultured in RPMI 1640 (+10 % FBS
supplemented with antibiotic solution containing penicillin
and streptomycin (Gibco). Repeated viability tests using a
Bürker chamber to count cultured BV-173 cells in the course
of successive passages always showed very high (~99 %)
viability. A few microliters of the BV-173 cell suspension
were added to a drop of fresh medium in a plastic petri
dish. Using a stereomicroscope, 10 and 100 leukemic cells
were retrieved with a 130 μm micropipette (Flexipet, COOK)
and placed in separate medium droplets.
Incorporation of cells into a fibrin matrix
Formation of fibrin clots was done as previously described by
Luyckx et al. [27]. A 12.5 μL fibrinogen droplet (Baxter,
Belgium) was placed on a glass petri dish. Fifty thousand
ovarian cells contained in 5 μL of medium and 10 or 100
leukemic cells (manually picked up with a micropipette under
the stereomicroscope) were successively added to the fibrino-
gen. The fibrinogen droplet containing the cells was mixed
with 12.5 μL of thrombin on a plastic petri dish and incubated
for 45 min at 37 °C for fibrin polymerization. The clot was
then gently detached for grafting.
For positive controls, 3 million BV-173 cells in 10 μL of
medium were incorporated into the fibrin clots in a similar
manner. A fibrin clot filled with cells is illustrated in Fig. 1a.
Xenografting of fibrin clots to SCID mice
Animal welfare guidelines were approved by the Committee
on Animal Research of the Université Catholique de Louvain.
Fourteen 6- to 9-week-old female SCID mice (Charles River
Laboratories) were used for this study. Housing conditions,
anesthesia and analgesia were previously described [26]. After
performing a ventral midline incision, a peritoneal pocket was
created on the right inner side of the peritoneum using non-
absorbable 6–0 Prolene suture (Fig. 1b). The inner peritoneal
surface was scratched with a scalpel [28], before gently
pushing the fibrin clot into the peritoneal pocket and closing
it with a stitch (Fig. 1c). Each mouse was grafted with a
fibrin clot containing either 10 (5 mice), 100 (5 mice) or 3
million (4 mice) leukemic cells. Atipamezole (1 mg/kg;
Antisedan, Pfizer) was used to reverse anesthesia after surgery.
Upon detection of a peritoneal mass or maximum 20weeks
after grafting, the mice were anesthetized using the same pro-
tocol as for the grafting procedure. Blood was retrieved by
intracardiac puncture. They were then euthanized by cervical
dislocation and bone marrow was collected by flushing fe-
murs with MEM-HEPES containing 10 % FBS. The perito-
neal grafts as well as the liver and spleen of each mouse were
recovered. The samples were cut into 3 and assigned to PCR
(Trizol Reagent), flow cytometry (MEM-HEPES + 10 %
FBS) and microscopic analysis (formol).
Detection of leukemia in mice
Histological analysis
Tissue fragments (peritoneal grafts, liver and spleen) assigned to
microscopic analysis were fixed in 4 % formaldehyde, embed-
ded in paraffin, and serially sectioned (5 μm). Every third slide
was stained with hematoxylin and eosin (Merck) for histological
evaluation. The remaining slides (SuperfrostPlus, Menzel-
Glaser) were kept for immunostaining.
Immunohistochemistry
Human anti-CD79α immunohistochemistry (IHC) was per-
formed on recovered grafts and livers (12 sections/sample).
CD79 is a transmembrane heterodimer (CD79α/CD79β) non-
covalently associated with surface immunoglobulin forming
the B-cell receptor complex required for antigen recognition.
Fig. 1 (a) Leukemic cells embedded in a fibrin clot observed under the
inverted microscope. (b and c) Grafting procedure and peritoneal bursa
formation. Black arrows (b) show the suture used for preparation of the
bursa, with the fibrin clot placed in the middle. The ends of the suture
were pulled and closed with a knot to obtain a closed bursa with the fibrin
clot inside (c)
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CD79α is considered a pan-B cell marker and is expressed by
BV-173 cells.
Sections were deparaffinized (Histosafe, Yvsolab SA) and
rehydrated in 2-propanol (Merck). After blocking endogenous
peroxidase activity with H2O2 0.3 %, a demasking step was
performed for 75 min at 98 °C with citrate buffer and Triton
X100. The sections were incubated for 30 min with 10 %
normal goat serum (NGS) and 1 % bovine serum albumin
(BSA, Sigma) to block non-specific binding sites, and then
with mouse anti-human CD79α antibody, 1:30 dilution
(Dako), at room temperature for 1 h. The slides were subse-
quently incubated with goat anti-mouse IgG (Envision,
DAKO) for 60 min at room temperature. Diaminobenzidine
was used as a chromogen (SK 4100, Vector Laboratories).
Counterstaining was performed with hematoxylin before
mounting the slides using DPX neutral mounting medium
(Prosan, Merelbeke, Belgium). Negative controls consisted
of the dilution solution without any anti-CD79α antibody.
BV-173 cells were used as positive controls.
Flow cytometry analysis
All flow cytometry analyses were carried out in an accredited
clinical flow cytometry laboratory specialized in onco-
hematology.
Upon reception of the cell line and just before grafting, the
complete BV-173 cell phenotype was verified by flow cytom-
etry using a Navios (3-laser) flow cytometer, as routinely per-
formed for acute lymphoid leukemia (ALL). For this purpose,
we used 2 orientation tubes and 3 tubes for intra-cytoplasmic
markers followed by 4 panels of 7 to 8 monoclonal antibodies
for B-type ALL characterization. Then, based on the deter-
mined BV-173 cell phenotype, we selected a combination of
markers (two 5-color panels, Fig. 3a) to allow differentiation
of our cell line from other cells (notably mature lymphocytes)
possibly present in our samples. Multiple markers were ap-
plied for more sensitive and specific cell detection. Conjugat-
ed reagents used for determining antigen expression were
FITC-CD13 (SJ1D1), FITC-CD44 (J-173), PE-CD10 (J5-
RD1), ECD-CD45 (J33), PC5-CD33 (D3HL60.251),PC5-
CD38 (LS-198-4-3)and PC7-CD19 (J4.119), all from
Immunotech, Beckman Coulter (BC). Both 5-color panels
were utilized for each sample, the second panel to confirm
the results of the first.
Each five-color panel was added to 100 μL of whole blood
or 50 μL liver, spleen, peritoneal graft or bone marrow cell
suspension after adjusting concentrations to 5–10×103 cells/
μL. The cell and monoclonal antibody mixture was then gent-
ly vortexed and incubated for 30 min. Four milliliters of
erythrocyte-lysing solution (for blood and bone marrow) or
Isoton (for liver, spleen and peritoneal grafts) was added to
each sample. The mixture was shaken and incubated for
10 min at room temperature. Finally, all the samples were
centrifuged (300g, 5 min) at room temperature and the pellets
resuspended in 1 mL of PBS.
For each sample, events were recorded over 300 s using a
FC500 (BC) flow cytometer equipped with 2 lasers: a 488
argon laser and a 633 red HeNe laser. Flow-Check ™
fluorospheres (BC) and Flow-Check 675 (APC (675/633) Set-
up Kit, BC) were used daily to assess flow cytometer optical
alignment and fluidic system performance, while light scatter
intensity and fluorescence intensity were controlled using
Flow-Set ™ fluorospheres (BC) and Flow-Set 675 (APC
(675/633) Setup Kit, BC), in order to evaluate optimal condi-
tions for quantitative analysis of human leukocytes.
The CXP 2.2 software (BC) was used for both, acquisition
and analysis purposes (listmode files). Cell targeting was car-
ried out after manual gating around the mononucleated popu-
lation on a forward vs. side-scatter dot plot. A second gate was
then placed on the B lymphocyte (CD-19 positive) subpopu-
lation (Fig. 3b–g), and the percentage of events expressing the
BV-173 cell phenotype was analyzed. A minimum of 20
events was the cut-off for positivity.
PCR analysis: detection of the BCR-ABL fusion gene
For PCR analysis of mouse blood and bone marrow, erythro-
cytes were lysed. Leukocytes obtained by centrifugation were
counted (Z1 Particle Counter, Coulter Corporation) and total
RNAwas extracted from 107 leukocytes with TriPure isolation
reagent (Roche Diagnostics) according to the manufacturer’s
recommendations. Solid tissues were ground and placed in
TRIzol reagent (Invitrogen) for RNA extraction. RNA con-
centrations were measured by fluorometry, and cDNA synthe-
sis followed by quantitative RT-PCR were performed using
the BCR-ABLMbcr IS-MMRDX kit (Ipsogen) following the
manufacturer’s instructions. Briefly, cDNA synthesis was
done with 1.5 μg of RNA in a volume of 15 μL, to which
22.5 μl of RT premix was added. After a first step at
25 °C for 10 min, then another at 37 °C for 60 min,
reverse transcription was halted by inactivation at 85 °C
for 10 min. Quantitative RT-PCR for each sample was
performed in a final volume of 25 μL, containing 5 μL
cDNA (200 ng of RNA equivalent). Thermal cycling
was started with an initial denaturation step at 95 °C
for 10 s, followed by 50 cycles at 95 °C for 5 s, then
60 °C for 30 s. Our samples and positive and negative
controls were amplified in simplicate. Positive controls
were commercial plasmid DNA calibrators containing
target gene sequences. For negative controls, we used
tissue from a healthy SCID mouse. Relative quantifica-
tion was performed by quantification cycle (Cq) analysis
and results were expressed as the ratio of the target
gene (BCR-ABL fusion transcript gene) vs. the house-
keeping gene (Abelson: ABL).
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Results
Macroscopic analysis
All 4 mice grafted with 3×106 leukemic cells developed pal-
pable peritoneal masses in the grafting site within 4 weeks. At
this stage, however, the mice still looked healthy and did not
show any clinical sign of terminal cancer (significant weight
loss or cachexia, ruffled coat, hunching). The size of the
masses is indicated in Table 1. Macroscopically, the masses
were hard, white and well vascularized (Fig. 2a). Mice grafted
with 10 or 100 leukemic cells did not develop any visible
masses and were euthanized after 20 weeks. Upon macro-
scopic evaluation, the grafts were found to have shrunk in
size as the fibrin was entirely degraded after 5 months.
Because of their very little size, they were difficult to dis-
tinguish from the peritoneum and were identified by the stitch
used to make the peritoneal bursa (as shown in Fig. 2d).
None of the mice showed enlarged abdominal nodes or
hepatosplenomegaly during dissection.
Histology and immunohistochemistry
Peritoneal masses Masses found in the 4 mice grafted with 3
million leukemic cells showed widespread invasion by lym-
phoblasts, all positive for anti-human CD79α (Fig. 2b).
Peritoneal grafts Grafted fibrin clots were identified at histol-
ogy, then anti-human vimentin IHC was performed to identify
human ovarian cells. Clots were present in fragments assigned
to microscopic analysis in 6 of the 10 mice (3 grafted with 10
BV-173 cells and 3 grafted with 100 BV-173 cells), while in
the remaining 4, it is likely that they were exclusively in frag-
ments assigned to PCR and/or flow cytometry, as all recov-
ered grafts were macroscopically cut into 3 pieces. In each
case, the part of the clot subjected to microscopic analysis
measured between 560 and 840 μm. They formed well
vascularized structures somewhat resembling normal ovarian
medullary tissue (Supplementary Fig 1). No signs of leukemic
invasion were detected at histology and anti-human CD79α
IHC performed on serial sections was also negative in all
cases, suggesting an absence of human leukemia B cells in
any of the grafts (Fig. 2e).
Mouse livers Three of the 4 mice grafted with 3 million leuke-
mic cells showed liver invasion at classical light microscopy,
and all 4 were positive for anti-human CD79α at IHC (Fig. 2c).
Livers frommice grafted with 10 or 100 leukemic cells were all
found to be disease-free at both histology and IHC (Fig. 2f).
Flow cytometry
BV-173 cell phenotype established by flow cytometry before
grafting was as follows: CD19+,CD3-,CD20-, CD33+,
Table 1 Summary of results for leukemic cell detection by immunohistochemistry (IHC), flow cytometry (FC) and PCR in mice grafted with 10, 100
or 3 million leukemic cells
Grafted BV-173 cells Mouse Macroscopic peritoneal mass Peritoneal graft Liver Spleen Blood Bone marrow
IHC FC PCR IHC FC PCR FC PCR FC PCR FC PCR
10 1 no − − − − − − − − − − − −
2 no − − − − − − − − − − − −
3 no − − − − − − − − − − − −
4 no − − − − − − − − − − − −
5 no − − − − − − − − − − − −
100 6 no − − − − − − − − − − − −
7 no − − − − − − − − − − − −
8 no − − − − − − − − − − − −
9 no − − − − − − − − − − − −
10 no − − − − − − − − − − − −
3×106 11 yes (1.2×0.9×0.7 cm) + + + + + + + + NP + NP +
12 yes (1×1×0.6 cm) + + + − − + − + − + + +
13 yes (1×1×0.7 cm) + + + + + + + + + + + +
14 yes (1×0.8×0.5 cm) + + + + − + − + + + − +
Neg ctrl 15 no NA NA NA − NA − NA − NA − NA −
Mice grafted with 10 or 100 leukemic cells showed no sign of leukemia in the different tissue samples by any of the techniques. All those grafted with 3
million leukemic cells developed leukemic masses in the grafting site and showed the presence of systemic disease.
NA not applicable, NP analysis not possible due to small sample volume
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CD79α+, CD13+, CD10+, CD22+, CD43+, CD44+, CD45-,
CD38+.
For the combination of markers selected for our experi-
ments (two 5-color panels, Fig. 3a), among the CD19 positive
mononucleated cell population, the following phenotypes
corresponded to our BV-173 cells: panel 1: CD45-/CD13+/
CD10+/CD33+; and panel 2: CD45-/CD10+/CD44+/CD38.
The percentage of BV-173 cells found in each sample is de-
tailed in Supplementary Table 1. In mice grafted with 10 or
100 leukemic cells, none of the tested samples showed any
contamination by leukemic cells (Fig. 3e–g). Flow cytometry
was not performed on blood or bone aspirate from mouse 11,
as there was not enough tissue to conduct both tests. Since our
previous results demonstrated that PCR was more sensitive
than flow cytometry for this application, the entire samples
were assigned to PCR. In the positive control group (3 million
cells), however, peritoneal masses exhibited between 15 and
57% BV-173 cells and at least one other tissue was positive in
each mouse, proving that the disease was already systemic
4 weeks after grafting (Supplementary Table 1).
PCR analysis
BV-173 cells express BCR-ABL fusion transcripts, allowing
detection of our cells with a sensitivity of 10−3 to 10−4,
depending on housekeeping gene expression (between 3200
and 32,000 ABL copies in our samples).
For the 4 mice grafted with 3×106 leukemic cells, all
samples (peritoneal masses and all recovered tissues) were
positive for the BCR-ABL leukemic marker (Table 1).
Conversely, none of the samples from mice grafted with
10 or 100 leukemic cells showed any signs of leukemic
cell contamination (Table 1).
Discussion
For patients with leukemia, malignant cells present in the
bloodstream could also be present in the ovary at the time of
cryopreservation [18]. There is currently no clinical alterna-
tive for these patients, whose only choice is OTC, but in
whom transplantation cannot be performed due to the risk of
reintroducing the disease. Fertility restoration techniques
using follicles from cryopreserved tissue as a source of gam-
etes are currently being investigated. In vitro follicle growth
and oocyte maturation followed by in vitro fertilization could
be an option. However, despite advances in the field, viable
embryos and live offspring generated by this technique have
only been achieved in mice so far [32–34], and major chal-
lenges remain to improve culture systems in humans to obtain
competent human oocytes [35].
Fig. 2 (a–c) Macroscopic and IHC analysis of a mouse grafted with
3×106 leukemic cells. Peritoneal masses were palpable 4 weeks after
grafting. The macroscopic view shows a hard, white and well
vascularized peritoneal mass in the grafting site (a). Microscopic
evaluation revealed widespread invasion of the mass by lymphocytic
cells positive for anti-human CD79α (b). Microscopic analysis of the
liver showed obvious leukemic invasion at histology, positive for anti-
human CD79α immunostaining (c). (d-f) Macroscopic and IHC analysis
of peritoneal grafts and liver recovered from amouse implanted with 100
leukemic cells. The grafts had shrunk in size and were identified by
the still present stitch in the peritoneal bursa (black arrow, d). No
human CD79α-positive cells were identified in the grafts (e). The
liver showed no sign of leukemic invasion at histology and was
negative for anti-CD79α at IHC (f)
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The need to find alternative fertility-restoring solutions for
these patients led us to investigate isolated follicle grafting and
launch the artificial ovary concept. Follicles isolated from
frozen-thawed ovarian tissue are embedded in 3-D matrices,
such as plasma clots [24, 25], alginate [26] or fibrin [27, 28],
along with ovarian stromal and endothelial cells, which allow
formation of a well vascularized ovary-like structure [29]. This
artificial ovary provides a more natural environment for follicle
survival and development. Our group demonstrated, for the first
time, the ability of isolated human preantral follicles embedded
in a plasma clot to grow to the antral stage after xenotransplan-
tation to mice [25]. Recent results on grafting of mouse follicles
and ovarian cells in fibrin are also promising [28].
However, since isolated follicles are retrieved from poten-
tially contaminated ovarian tissue suspensions, it is vital to
ensure that suspensions are free of malignant cells before they
are incorporated into the artificial ovary. Experiments were
recently conducted in an in vitro model of ovarian tissue arti-
ficially contaminated with leukemic BV-173 cells, and a study
on the safe isolation of follicles from tissue of leukemia pa-
tients is ongoing. The present study was initiated to investigate
the leukemia-inducing potential of a few leukemic cells in an
artificial ovary environment.
Several studies carried out in male rodent models have
attempted to determine the number of leukemic cells in
testicular tissue or testicular cell suspensions needed to
a
b c d
e f g
Fig. 3 (a) Two 5-color monoclonal antibody panels used for detection of
the BV-173 cell line in our samples. (b–g) Gating strategy for flow
cytometry detection of leukemic cells in bone marrow samples from a
mouse grafted with 3×106 leukemic cells (b–d) and 100 leukemic cells
(e–g). For the sake of clarity, only one example with panel 1 is shown in
the figure. (b and e) Manual selection of the mononucleated population
(gate A) on a bi-parametric dot plot with side scatter vs. forward scatter (c
and f). Selection of CD19(PC7)-expressing cells (gate C) by a second
manual gating. (d and g) Expression of CD33 and CD10 on a bi-
parametric dot plot gated on A and C. BV-173 cells (CD19+, CD33+,
CD10+) are colored in blue (d). In mice grafted with 10 or 100 leukemic
cells, no BV-173 cells were identified (g)
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induce leukemia. Results differ between studies, but
intratesticular [36] or intraperitoneal [37] injection of as
few as 10 AML cells was found to induce disease in
mice. The type of cell line used and its species-specific
origin could also have an impact on the results. In a study
using rat T leukemia cells [38], intratesticular injection of
at least 20 cells was capable of inducing leukemia in rats
within 21 days. When these same cells were injected in-
traperitoneally into nude mice, a minimum of 200 cells
was required to induce leukemia [39]. These results indi-
cate that host species and grafting site may influence the
number of grafted cells and time required to induce leukemia.
The microenviroment is also known to play an important role
in tumor development [40], and interleukin-1, which is nota-
bly produced in the testis, may promote proliferation of leu-
kemic cells in male.
No such study has yet been performed with ovarian tissue,
and although cryopreserved ovarian tissue from leukemia pa-
tients was shown to induce tumors when grafted to SCIDmice
[18], the number of leukemic cells present in the tissuewas not
known. Our study is the first to evaluate the survival and
tumor-inducing capacity of leukemic cells in an artificial ova-
ry environment. The number of grafted leukemic cells grafted
was based on results from a previous study using a model of
artificially contaminated ovarian tissue, in which between 1
and 97 leukemic cells were found in the follicle suspension
(Soares et al., submitted). We embedded these leukemic cells
in a fibrin matrix along with 50,000 ovarian cells, as in our
previous studies on the artificial ovary [26, 28]. In a clinical
setting, the artificial ovary would be grafted, like cryopre-
served ovarian cortex, either to the remaining ovary and/or
inside a peritoneal window, both sites having proved equally
effective [41, 42]. In our experiment, in order to mimic con-
ditions inside the peritoneum, clots were grafted to its inner
surface, inside a peritoneal pocket. Fibrin is known to provide
a good environment for cell migration and proliferation, and
serves as a reservoir of growth factors. Furthermore, it plays
an important role in angiogenesis. Fingert et al. [43] reported
that leukemic cells were able to survive and grow in a fibrin
matrix when transplanted to the kidney capsule.
In our study, all mice grafted with 3×106 cells developed
systemic disease within 4 weeks, but there was no sign of
leukemia in mice grafted with 10 or 100 BV-173 cells after
20 weeks. In general, the rate of disease appearance is directly
related to the number of transferred lymphoblasts [37, 44].
BV-173 cells have a doubling time of 30–48 h, so 5 months
appeared more than adequate for our purposes. The maximum
evaluation period in previous studies was 4 months [36].
Flow cytometry is a very sensitive method for leukemic
cell detection. In our study, however, PCR proved more sen-
sitive than flow cytometry, as certain samples negative at flow
cytometry were found to be positive by PCR (mice 12 and 14).
The lower sensitivity of our flow cytometry analysis was
probably due to small sample volumes available for this tech-
nique, and also low levels of infiltration of certain samples by
BV-173 cells. The scant cellularity of BV-173 cells could not
therefore be compensated for by analysis of bigger volumes.
Because grafting of an artificial ovary is an avascular pro-
cedure, post-grafting ischemia, occurring before the revascu-
larization process is activated, could explain the loss of a cer-
tain percentage of cells by hypoxia, be it ovarian or leukemic.
Moreover, the immunodeficient SCID mouse model used
in this study is characterized by some residual immunity (nat-
ural killer cells, macrophages and granulocytes), which might
confer a protective effect against tumor engraftment. Women
in cancer remission are immunocompetent hosts, so their im-
mune response may well act as an effective extrinsic tumor-
suppressing system [45].
In a clinical setting, no risks should be taken and grafted
follicles should be completely free of leukemic cells. We are
currently working on the safe isolation of follicles from pa-
tients at risk of minimal residual disease.
Conclusion
This is the first study to evaluate the tumor-inducing potential
of a few leukemic cells grafted inside an artificial ovary. Mice
grafted with 10 or 100 BV-173 leukemic cells did not develop
any sign of leukemia after 20 weeks. These results are
reassuring as they suggest that as many as 100 BV-173 cells
inadvertently grafted inside an artificial ovary are not capable
of inducing leukemia, even in an immunodeficient xenograft-
ing model. However, in a clinical context, even the slightest
risk should be avoided. Purging follicle suspensions of malig-
nant cells is therefore a must to ensure a malignant cell-free
follicle suspension before grafting.
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